--- title: 'Senior Director, Quality Control at Nurix' canonical: 'https://feeny.ai/job/senior-director-quality-control-nurix-brisbane-california-d4hqe06vb3t7' type: 'job' last_seen: '2026-09-09' --- # Senior Director, Quality Control at Nurix - **Company:** Nurix - **Location:** Brisbane California, United States - **Posted:** 2026-09-07 - **Last confirmed live:** 2026-09-09 - **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8784989002 ## Job description Associate Director, Chemical Engineering Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Position Description Nurix is seeking an experienced, independent, and highly motivated individual who will be accountable for end‑to‑end chemical engineering support of bexobrutideg (NX-5948) drug substance (DS) from late‑stage development through commercial launch, including oversight of external manufacturing sites. The Associate Director, Chemical Engineering will work closely with the CMC team and colleagues in cross-functional departments to provide scientific, technical, and hands-on leadership and oversight of facility and equipment operations at Contract Development Manufacturing Organizations (CDMOs) to support bexobrutideg drug substance manufacturing process optimization and scale-up. The position will report to the Director, Chemical Development. Responsibilities will include but are not limited to: - Provide engineering leadership to design, develop and optimize scalable routes for small-molecule DS manufacturing, including demonstrated knowledge in unit operation design, process modeling, process equipment selection and scale-up methodologies. - Review equipment configurations, qualification packages, and maintenance records at CDMOs to ensure equipment trains are properly qualified, maintained and operating at optimal performance to support Nurix manufacturing operations. - Oversee equipment engineering and scale-up operations at DS CDMOs, including hands‑on process troubleshooting during engineering, clinical, registration and PPQ batches. - Lead technology transfer to CDMOs including scale-up and demonstration of new chemical processes in development and commercial equipment. - Coordinate with CDMOs and Nurix Quality Assurance, and Global Supply Chain functions to ensure timely manufacture and release of DS lots. - Partner within Nurix CMC to drive process understanding (critical process parameters, critical quality attributes, control strategy) using engineering principles, DoE and QbD concepts. - Review and approve Master Batch Records, campaign reports, deviation investigations and change controls for drug substance operations. - Ensure manufacturing operations adhere to company quality, safety and regulatory standards (FDA, EMA, ICH, cGMP). - Provide regular Person-In-Plant support for DS manufacturing and ongoing performance monitoring of key facility and operational KPIs across manufacturing sites, including schedule adherence, batch performance, deviation trends, and inspection readiness. - Author and review CMC sections of regulatory filings including INDs/IMPD, and NDA/MAA, including responses to Health Authority queries. - Define and drive the long‑term engineering strategy for bexobrutideg DS, including process robustness, lifecycle management, and cost‑of‑goods optimization. - Represent Chemical Engineering on CMC and cross‑functional program teams, providing input to development strategy, risk assessments, and timelines. - Manage and provide technical mentorship of scientists and engineers. Required Qualifications - Ph.D. in chemical engineering, or related field with at least 5 years (M.S. with 10 years or B.S. with 15 years) of industrial, late-phase, small-molecule drug substance development experience - Extensive knowledge and experience in GMP drug substance manufacturing, characterization, process development, equipment evaluation/selection, scale up and process validation. - Knowledge of solid‑state properties, polymorphism, and crystallization principles relevant to small‑molecule drug substance. - Extensive third-party drug substance CDMO management experience including tech transfer activities, QbD and DoE studies, clinical supply production, registration batch production and commercial launch activities. - In-depth knowledge of relevant cGMP, ICH, FDA and EMA guidelines. - Proven track record of effective internal and external collaboration. - Excellent oral and written communication skills, interpersonal skills and problem-solving abilities. - Ability to multi-task, manage conflict and work in a fast-paced environment. - Ability to travel up to 25% of their time. Fit with Nurix Culture and Values - Strong team orientation; highly collaborative - Solutions and results-oriented focus - Hands-on approach; resourceful and open to diverse points of view Salary Range:   $189,800 - $216,700 Location:         Brisbane, CA - Onsite ## About Nurix ## Company Overview - **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system. - **Entity Type**: Public (NASDAQ: NRIX) - **Headquarters**: San Francisco, California, USA - **Founded**: 2009 - **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco. ## Core Business - **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation - **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma. - **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/) ## Products & Services - **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/) - **NX-2127**: A BTK degrader in clinical development for B-cell malignancies. - **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials. - **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases. - **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies. - **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs). ## Market Standing - **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure. - **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results. - **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program). - **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages. ## Competitive Advantages - **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/) - **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat. - **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal. - **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk. ## Strategic Focus - **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology. - **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety. - **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships. - **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines. ## Why Work Here - **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) - **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) - **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences. - **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/) - **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) - **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/) ## Sources 1. [nurixtx.com](https://www.nurixtx.com/) 2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) 3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/) 4. [nurixtx.com](https://www.nurixtx.com/our-story/) ## Other roles at Nurix - [Associate Director, electronic Quality Management System (eQMS)](https://feeny.ai/job/associate-director-electronic-quality-management-system-eqms-nurix-brisbane-k35rdgj6th4k) — Brisbane, CA - [Director, Nonclinical Toxicology Operations](https://feeny.ai/job/director-nonclinical-toxicology-operations-nurix-brisbane-california-a7ynjr847xvh) — Brisbane California, United States - [Director, Medical Affairs - Immunology](https://feeny.ai/job/director-medical-affairs-immunology-nurix-brisbane-california-8q3w67dea5xq) — Brisbane California, United States - [Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-strategy-hematology-zsgdf1qycbew) — Brisbane California, United States - [Senior Administrative Assistant, R&ED](https://feeny.ai/job/senior-administrative-assistant-r-ed-nurix-brisbane-california-9k9rhmyvd955) — Brisbane California, United States - [Associate Director, Chemical Engineering](https://feeny.ai/job/associate-director-chemical-engineering-nurix-brisbane-california-6gbpc8ben8eh) — Brisbane California, United States - [Senior Analyst, FP&A](https://feeny.ai/job/senior-analyst-fp-a-nurix-brisbane-california-g7qxkkvsfwbf) — Brisbane California, United States - [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-wkgs5dx1e7eq) — Brisbane California, United States - [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-57ydhjmqgfm6) — Brisbane California, United States - [Medical Director / Senior Medical Director 5948-306](https://feeny.ai/job/medical-director-senior-medical-director-5948-306-nurix-brisbane-california-4130rhzkqwev) — Brisbane California, United States